\u00d6zel sekt\u00f6rde \u00e7al\u0131\u015fan 41 ya\u015f\u0131ndaki B.A\u2019ya, May\u0131s 2020 y\u0131l\u0131nda beyin, karaci\u011fer, kemik ve lenflere metastaz yapm\u0131\u015f meme kanseri tan\u0131s\u0131 konuldu. B.A\u2019n\u0131n tedavisi s\u00fcrerken i\u015finden ayr\u0131ld\u0131 ve bir y\u0131l \u00f6nce Sosyal G\u00fcvenlik Kurumu\u2019ndan (SGK) malulen emekli oldu. Bu s\u00fcre\u00e7te B.A. i\u00e7in T\u00fcrkiye\u2019de faydal\u0131 olabilecek t\u00fcm ila\u00e7lar kullan\u0131ld\u0131.<\/p>\n
\u0130la\u00e7lar\u0131n yetersiz kalmas\u0131 sonucu tedaviyi y\u00fcr\u00fcten doktorlar taraf\u0131ndan ABD G\u0131da ve \u0130la\u00e7 Dairesi taraf\u0131ndan (FDA) 2022 y\u0131l\u0131nda onaylanan \u0130ngiliz ve Japon ila\u00e7 firmas\u0131 taraf\u0131ndan piyasaya sunulan\u00a0\u201cTrastuzumab deruxtecan\u201d etken maddeli ilac\u0131n kullan\u0131lmas\u0131 gerekti\u011fi belirtildi. Bunun \u00fczerine hasta yak\u0131nlar\u0131 taraf\u0131ndan ilac\u0131n kullan\u0131m\u0131 i\u00e7in T\u00fcrkiye \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumuna yap\u0131lan ba\u015fvuru uygun bulundu.<\/p>\n
Ancak ilac\u0131n temini i\u00e7in yap\u0131lan ba\u015fvuru, \u0130bni Sina Sa\u011fl\u0131k Sosyal G\u00fcvenlik Merkezi taraf\u0131ndan 12 Ekim 2022\u2019de reddedildi. Bunun \u00fczerine hasta yak\u0131nlar\u0131, bedeli y\u00fcksek olan ilac\u0131n kullan\u0131lmamas\u0131 halinde B.A\u2019n\u0131n hayat\u0131n\u0131n tehlikeye girece\u011fi, s\u00f6z konusu ilac\u0131n bedelinin kesintisiz ve \u00fccretsiz olarak SGK taraf\u0131ndan taraf\u0131ndan kar\u015f\u0131lanmas\u0131 i\u00e7in ihtiyati tedbir talebiyle dava a\u00e7t\u0131.<\/p>\n
DAVA SONUNA KADAR \u0130LA\u00c7 BEDEL\u0130 KAR\u015eILANACAK<\/strong><\/p>\n Talebi de\u011ferlendiren Ankara 33. \u0130\u015f Mahkemesi, \u201cSosyal devlet, sosyal g\u00fcvenlik hakk\u0131 kapsam\u0131nda herkesin hayat\u0131, beden ve ruh sa\u011fl\u0131\u011f\u0131 i\u00e7inde s\u00fcrd\u00fcrmesini sa\u011flamakla y\u00fck\u00fcml\u00fcd\u00fcr. Davac\u0131n\u0131n hastal\u0131\u011f\u0131n\u0131n niteli\u011fi g\u00f6zetildi\u011finde ilac\u0131n tedavi edici olup olmad\u0131\u011f\u0131n\u0131 irdelemeden kanser hastas\u0131n\u0131n ya\u015fama umudunu desteklemesi dahi yeterli g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Davac\u0131n\u0131n re\u00e7ete edilen ilac\u0131 kullan\u0131lmamas\u0131 halinde ileride telafisi imkans\u0131z zararlara yol a\u00e7aca\u011f\u0131 kanaatiyle tedbir isteminin kabul\u00fcne karar verilmi\u015ftir\u201d dedi.<\/p>\n Mahkeme, dava sonuna kadar \u2018trastuzumab deruxtecan\u2019 ilac\u0131n bedelinin herhangi bir kesinti yap\u0131lmaks\u0131z\u0131n Sosyal G\u00fcvenlik Kurumu taraf\u0131ndan kar\u015f\u0131lanmas\u0131na ve ilac\u0131n ithali i\u00e7in gerekli \u00f6demenin do\u011frudan ithale yetkili T\u00fcrkiye Eczac\u0131lar Birli\u011fi Yurt D\u0131\u015f\u0131ndan \u0130la\u00e7 Temin Birimi\u2019ne yap\u0131lmas\u0131na h\u00fckmetti.<\/p>\n \u201cKARAR MEME KANSER\u0130YLE M\u00dcCADELE EDEN KADINLARA UMUT I\u015eI\u011eI\u201d<\/strong><\/p>\n Konuya ili\u015fkin ailenin avukat\u0131 Zehra Bet\u00fcl Bulut, m\u00fcvekkili i\u00e7in bu zamana kadar uygulanan geleneksel tedavi y\u00f6ntemlerinin t\u00fcketilmesi ve doktorunun meme kanseri tedavisinde standart tedaviye yeni girmi\u015f olan \u2018trastuzumab deruxtecan\u2019 etken maddeli ilac\u0131n kullan\u0131lmas\u0131n\u0131 \u00f6nermesi nedeniyle ilac\u0131n yurt d\u0131\u015f\u0131ndan temin edildi\u011fini, ancak bu ilac\u0131n SGK\u2019n\u0131n \u00f6deme listesinde bulunan ila\u00e7lar aras\u0131nda yer almad\u0131\u011f\u0131n\u0131 belirtti.<\/p>\n \u0130lac\u0131n SGK taraf\u0131ndan yurtd\u0131\u015f\u0131ndan getirilmesi ve masraf\u0131n\u0131n kar\u015f\u0131lanmas\u0131 i\u00e7in biz \u00f6ncelikle SGK\u2019ya yapt\u0131klar\u0131 ba\u015fvurunun reddedilmesi \u00fczerine ilac\u0131n teminine y\u00f6nelik dava a\u00e7t\u0131klar\u0131n\u0131 ifade eden Bulut, \u015funlar\u0131 s\u00f6yledi:<\/p>\n * \u201cRe\u00e7ete edilen ilac\u0131n kullan\u0131lmamas\u0131 halinde ileride telafisi imkans\u0131z durumlara yol a\u00e7mamas\u0131 nedeniyle ihtiyati tedbir talebinde bulunduk. Mahkeme davay\u0131 a\u00e7t\u0131\u011f\u0131m\u0131z g\u00fcn i\u00e7erisinde talebimizi hakl\u0131 buldu ve Anayasal sa\u011fl\u0131k ve ya\u015fam hakk\u0131na dayanarak talebimizi kabul etti. Mahkeme karar\u0131yla birlikte SGK, m\u00fcvekkilime yurt d\u0131\u015f\u0131ndan ila\u00e7 teminini sa\u011flayacak ve ila\u00e7 masraf\u0131n\u0131 kesinti yapmaks\u0131z\u0131n kar\u015f\u0131layacak. Bu karar \u2018trastuzumab deruxtecan\u2019 etken maddeli kanser ilac\u0131 y\u00f6n\u00fcnden emsal karar niteli\u011fi ta\u015f\u0131maktad\u0131r.<\/p>\n * SGK\u2019n\u0131n s\u00f6z konusu \u00a0ilac\u0131 kanser hastalar\u0131na sa\u011flamas\u0131 y\u00f6n\u00fcnde al\u0131nan bu kararla, meme kanseri ile m\u00fccadele eden kad\u0131nlara umut \u0131\u015f\u0131\u011f\u0131 oldu\u011fumuza inan\u0131yorum. Bu m\u00fccadeleyi meme kanseriyle m\u00fccadelede kad\u0131n dayan\u0131\u015fmas\u0131 olarak da addedebilirsiniz. Sosyal devlet, sosyal g\u00fcvenlik hakk\u0131 kapsam\u0131nda herkesin hayat\u0131n\u0131, beden ve ruh sa\u011fl\u0131\u011f\u0131 i\u00e7inde s\u00fcrd\u00fcrmesini sa\u011flamakla y\u00fck\u00fcml\u00fcd\u00fcr, meme kanseriyle m\u00fccadele eden kad\u0131nlar bu hakk\u0131n temini i\u00e7in m\u00fccadele veriyor. Ben de hem bir kad\u0131n hem de bir avukat olarak mensubu oldu\u011fum yarg\u0131n\u0131n bu hakl\u0131 talebi desteklemesine \u00e7ok sevindim.\u201d DHA<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130stanbul’da meme kanseri hastas\u0131 B.A., yurt d\u0131\u015f\u0131ndan ithal edildi\u011fi gerek\u00e7esiyle SGK’n\u0131n \u00f6demedi\u011fi tek kutusu 39 bin 107 liral\u0131k (2 bin 19 euro) ila\u00e7 i\u00e7in dava a\u00e7t\u0131. \u0130htiyati tedbir talebiyle a\u00e7\u0131lan davay\u0131 kabul eden mahkeme, dava sonu\u00e7lan\u0131ncaya kadar ilac\u0131n paras\u0131n\u0131n SGK taraf\u0131ndan \u00f6denmesine h\u00fckmetti.<\/p>\n","protected":false},"author":1,"featured_media":57190,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[775,1564,1134,2437,845],"class_list":["post-57189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-dava","tag-ilac","tag-ilacin","tag-sgk","tag-tarafindan"],"_links":{"self":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/57189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57189"}],"version-history":[{"count":1,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/57189\/revisions"}],"predecessor-version":[{"id":57191,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/57189\/revisions\/57191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/media\/57190"}],"wp:attachment":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}